Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2017 Oct 19

PMID 29043654

Citations 17

Authors

Marta Niwald

Monika Migdalska-Sek

Ewa Brzezianska-Lasota

Elzbieta Miller

Affiliations

Soon will be listed here.

Abstract

Accumulating data suggests that miRNAs might play a major role in neuroinflammatory processes. Therefore, our study aimed to first estimate the levels of miR-155, miR-326, and miR-301a in serum of RR-MS patients in the remission phase and then compare the levels of the examined miRNAs at different times after relapse. In this study, 36 RR-MS patients in the remission phase took part. We analyzed two subgroups of RR-MS: one, 1 to 2 months after completing steroid treatment during relapse (post-acute; n = 13) and the other, over 2 years without any relapse (stable; n = 23). Moreover, we made correlations between these biochemical results and clinical parameters of cognitive impairment, depression, and disability. The obtained results presented downregulation of miR-155 and miR-301a (in 94% and 51% samples, respectively) and overexpression of miR-326 (in 72% samples) in RR-MS patients. Moreover, we observed a positive correlation between the relative expression of miRNAs and BDI (Beck Depression Index) for miR-326 (rho = 0.385459, p = 0.022210; Spearman's rank correlation) and miR-301a (rho = 0.435131, p = 0.008991; Spearman rank correlation). We also observed the differences in expression levels between the post-acute and stable phases of RR-MS. The expression levels of miR-301a and miR155 were higher in the post-acute vs. stable phase of remission (2.385 vs. 0.524 and 0.594 vs. 0.147; respectively). Our study, for the first time, presents miRNA expression differences in two stages of remission: post-acute and stable.

Citing Articles

Anti-NMDA Receptor Encephalitis, Human Papillomavirus, and microRNA.

Wang H Curr Med Chem. 2024; 32(4):771-787.

PMID: 38549528 DOI: 10.2174/0109298673264615231124072130.

Exosome Content-Mediated Signaling Pathways in Multiple Sclerosis.

Mohammadinasr M, Montazersaheb S, Ayromlou H, Hosseini V, Molavi O, Hejazi M Mol Neurobiol. 2024; 61(8):5404-5417.

PMID: 38191693 DOI: 10.1007/s12035-023-03862-2.

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.

Casanova I, Dominguez-Mozo M, De Torres L, Aladro-Benito Y, Garcia-Martinez A, Gomez P Biomedicines. 2023; 11(10).

PMID: 37893133 PMC: 10604830. DOI: 10.3390/biomedicines11102760.

MicroRNA‑155 modulation of CD8 T‑cell activity personalizes response to disease‑modifying therapies of patients with relapsing‑remitting multiple sclerosis.

Elkhodiry A, Zamzam D, El Tayebi H Med Int (Lond). 2023; 3(2):20.

PMID: 37032715 PMC: 10080195. DOI: 10.3892/mi.2023.80.

Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature.

Redensek Trampuz S, Vogrinc D, Goricar K, Dolzan V Front Mol Neurosci. 2023; 16:1123955.

PMID: 37008787 PMC: 10064073. DOI: 10.3389/fnmol.2023.1123955.

References

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y . Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci. 2014; 11(8):810-8. PMC: 4057480. DOI: 10.7150/ijms.8647. View

Lublin F, Reingold S . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4):907-11. DOI: 10.1212/wnl.46.4.907. View

OConnell R, Kahn D, Gibson W, Round J, Scholz R, Chaudhuri A . MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010; 33(4):607-19. PMC: 2966521. DOI: 10.1016/j.immuni.2010.09.009. View

Kim J, Krichevsky A, Grad Y, Hayes G, Kosik K, Church G . Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A. 2003; 101(1):360-5. PMC: 314190. DOI: 10.1073/pnas.2333854100. View

de Faria Jr O, Moore C, Kennedy T, Antel J, Bar-Or A, Dhaunchak A . MicroRNA dysregulation in multiple sclerosis. Front Genet. 2013; 3:311. PMC: 3551282. DOI: 10.3389/fgene.2012.00311. View

Niwa R, Slack F . The evolution of animal microRNA function. Curr Opin Genet Dev. 2007; 17(2):145-50. DOI: 10.1016/j.gde.2007.02.004. View

Paraboschi E, Solda G, Gemmati D, Orioli E, Zeri G, Benedetti M . Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2012; 12(12):8695-712. PMC: 3257096. DOI: 10.3390/ijms12128695. View

Zhao X, He X, Han X, Yu Y, Ye F, Chen Y . MicroRNA-mediated control of oligodendrocyte differentiation. Neuron. 2010; 65(5):612-26. PMC: 2855245. DOI: 10.1016/j.neuron.2010.02.018. View

10.

OConnell R, Rao D, Baltimore D . microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012; 30:295-312. DOI: 10.1146/annurev-immunol-020711-075013. View

11.

Siegel S, Mackenzie J, Chaplin G, Jablonski N, Griffiths L . Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep. 2012; 39(5):6219-25. DOI: 10.1007/s11033-011-1441-7. View

12.

Kacperska M, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A . Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study. J Mol Neurosci. 2014; 56(1):154-63. PMC: 4382531. DOI: 10.1007/s12031-014-0476-3. View

13.

Huang L, Liu Y, Wang L, Chen R, Ge W, Lin Z . Down-regulation of miR-301a suppresses pro-inflammatory cytokines in Toll-like receptor-triggered macrophages. Immunology. 2013; 140(3):314-22. PMC: 3800436. DOI: 10.1111/imm.12139. View

14.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain M . Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013; 73(6):729-40. DOI: 10.1002/ana.23880. View

15.

Wang K, Zhang S, Weber J, Baxter D, Galas D . Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010; 38(20):7248-59. PMC: 2978372. DOI: 10.1093/nar/gkq601. View

16.

Liu X, Leung S, Wang C, Tan Z, Wang J, Guo T . Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med. 2010; 16(2):191-7. DOI: 10.1038/nm.2077. View

17.

Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S . MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10(12):1252-9. DOI: 10.1038/ni.1798. View

18.

Devier D, Lovera J, Lukiw W . Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration. Front Mol Neurosci. 2015; 8:5. PMC: 4345893. DOI: 10.3389/fnmol.2015.00005. View

19.

Fenoglio C, Ridolfi E, Galimberti D, Scarpini E . MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci. 2012; 13(10):13227-39. PMC: 3497323. DOI: 10.3390/ijms131013227. View

20.

Grasso M, Piscopo P, Confaloni A, Denti M . Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules. 2014; 19(5):6891-910. PMC: 6271879. DOI: 10.3390/molecules19056891. View